



You are here: Home > Pharmacy News | Health Articles/Tips > International Pharma Industry News > April 15, 2011
Adventrx Pharma Acquiring SynthRxPosted Atdrugdiscovery.pharmaceutical-business-review.comAdventrx Pharmaceuticals, a specialty pharmaceutical company engaged in acquiring, developing and commercializing proprietary product candidates, has taken over SynthRx, under a definitive merger agreement signed between the companies in February 2011. Following the acquisition, SynthRx's lead product candidate, poloxamer 188, a novel, proprietary, rheologic and antithrombotic compound, will be developed by Adventrx as ANX-188. Adventrx CEO Brian Culley said their plan to meet with FDA this year to reach agreement on a protocol for a pivotal phase 3 study for treatment of sickle cell crisis in a pediatric population, an orphan indication. April 15, 2011
|